Dose-dense weekly docetaxel and CBDCA in adriamycin-resistant metastatic breast cancer (MBC)

Salimi, Mohamad; Mir, Mostafa

doi:10.1016/s0959-8049(98)80167-6

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other DTX combinations with cisplatin (16), carboplatin (17), fluorouracil (18) or gemcitabine (19) have yielded comparable response rates, but sustained responses have rarely been reported. The response rate, time to progression and overall survival with DTX'/VNB appear to be better than those observed with DTX alone, used as second-line therapy and tested in three randomized trials (20).…”

Section: Discussionmentioning

confidence: 99%

Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer

et al. 2003

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer

et al. 2003

View full text Add to dashboard Cite

“…With the cisplatin analogue carboplatin used as single agent, response rates of up to 35% can be achieved in first-or second-line treatment [3][4][5][6]. Carboplatin in combination with taxoids has yielded response rates between 44 and 80% in first-or second-line treatment [7][8][9][10][11][12]. For carboplatin combined with etoposide, response rates between 0 and 50% in first-or second-line treatment [13][14][15][16][17][18] have been reported.…”

Section: Introductionmentioning

confidence: 99%

Effective Salvage Therapy with Carboplatin/Mitomycin C in Metastatic Breast Cancer

et al. 2002

View full text Add to dashboard Cite

Background: Alternative and effective drug regimens in patients with metastatic breast cancer progressing after adriamycin- and taxoid-containing regimens are urgently needed. Patients and Methods: In a phase II trial, 43 heavily pretreated patients with metastatic breast cancer were treated with both carboplatin 200 mg/m² i.v. and mitomycin C 10 mg/m² i.v. on day 1 every 4 weeks. In case of granulocytopenia or thrombocytopenia below grade 3 according to NCI-CTC, the carboplatin dosage was escalated to 300, 400, and 450 mg/m² in the next treatment cycle. Results: During the first 3 cycles the dose intensity of carboplatin could be increased from a mean of 50 to 74 mg/m²/week. Beyond this value the carboplatin dose intensity decreased because of hematotoxicity. Based on an intention-to-treat analysis, 9 of 43 patients responded to therapy (21%; 95% CI = 10.04–36.04) including 2 complete and 7 partial responses. 15 patients had no change, 13 progressed, and 6 patients were considered nonevaluable. The median time to progression was 3 (range 0–12) months. NCI-CTC grade 3 or 4 granulocytopenia was observed in 14 patients, grade 3 or 4 thrombocytopenia occurred in 32, grade 3 infections in 3, grade 3 hemorrhage in 1, and grade 3 cardiac dysrhythmias in 1 of the patients. Conclusions: In anthracycline/ taxoid-pretreated patients, salvage treatment with a combination of carboplatin and mitomycin C seems to be effective and associated with foreseeable toxicity. Based on our results with an intraindividual dose escalation of carboplatin, a dosage of 300 mg/m² in combination with mitomycin C 10 mg/m² every 4 weeks seems to represent a recommendable starting dose for future studies.

show abstract

Dose-dense weekly docetaxel and CBDCA in adriamycin-resistant metastatic breast cancer (MBC)

Cited by 2 publications

References 0 publications

Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer

Clinical Data and Pharmacokinetics of a Docetaxel-vinorelbine Combination in Anthracycline Resistant/Relapsed Metastatic Breast Cancer

Effective Salvage Therapy with Carboplatin/Mitomycin C in Metastatic Breast Cancer

Contact Info

Product

Resources

About